Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.66 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.63 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102215 | 0.80 | PIM1 (1.00) | PIM1PIM2FLT3 | |
| SCHEMBL19987117 | 0.78 | PIM1 (0.58) | PIM1PIM2FLT3NTRK1TGFBR2 | |
| SCHEMBL4594847 | 0.77 | PIM1 (0.51) | PIM1PIM2FLT3NTRK1TGFBR2 | |
| SCHEMBL4595601 | 0.76 | PIM1 (0.49) | PIM1PIM2FLT3NTRK1 | |
| SCHEMBL19986933 | 0.76 | PIM1 (0.61) | PIM1PIM2FLT3TGFBR2 | |
| SCHEMBL103371 | 0.73 | PIM1 (0.58) | PIM1PIM2FLT3TGFBR2 | |
| SCHEMBL8207947 | 0.73 | PIM1 (0.61) | PIM1PIM2FLT3NTRK1TGFBR2 | |
| SCHEMBL19987012 | 0.71 | PIM1 (0.82) | PIM1PIM2FLT3 | |
| SCHEMBL4336441 | 0.71 | PIM1 (0.78) | PIM1PIM2FLT3 | |
| SCHEMBL102968 | 0.70 | PIM1 (1.00) | PIM1PIM2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734205-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2018-03-21 | — | — | EP | disclosed |